Register Now: Engineering LNP's Beyond the Liver for Genetic Medicines
|Articles|February 6, 2023

BP Elements

  • BioPharm International's BP Elements, February 2023
  • Volume 2
  • Issue 2

Thermo Fisher Scientific Announces Founding Sponsorship of Momentum Labs

Thermo Fisher’s sponsorship of Momentum Labs is intended to support biotech businesses in the greater Gainesville region.

Thermo Fisher Scientific recently announced that it had become a founding sponsor of Momentum Labs, a collaborative laboratory and office space to be located in Alachua, Fla. The venture, spearheaded by Gainesville real estate development firm Concept Companies, is designed to serve as a collaborative space for biotech businesses in the greater Gainesville region.

According to a Jan. 12, 2023 company press release, the north central region of Florida is home to more than 100 life sciences companies, but lacks the flexible growth space to help emerging companies succeed. Momentum Labs is intended to fill this gap, providing life sciences companies the ability to scale up without moving to other markets.

“From a regional and state perspective, Momentum Labs provides critical infrastructure and business development resources to support the growth of life sciences in Florida, giving the ecosystem the opportunity to retain companies rather than losing them to other communities,” said Abhinav Akhoury, vice-president, corporate accounts, Thermo Fisher Scientific, in the release. “Through our sponsorship, Momentum Labs has the ability to provide the latest innovative technologies to high-growth life science companies that are developing tomorrow’s life-changing medicines.”

“It’s challenging for growing companies to stay ahead of their space needs,” said Brian Crawford, CEO, Concept Companies, in the release. “Not only is there a large expense for all the equipment needed, but there are also often extraordinary lead times associated with the acquisition and installation. Partnering with Thermo Fisher Scientific gives us the ability to offer the latest innovative instrumentation and equipment to our members allowing them to leverage their capital for growth.”

Source: Thermo Fisher Scientific


Related to this article

Stainless steel bioreactor vessels in a manufacturing facility. | Image Credit: © Corona Borealis - stock.adobe.com
Four cell therapy developers have pulled back from ex vivo manufacturing in the past month — ArsenalBio, TScan Therapeutics, and Cellectis all pivoted to in vivo approaches, while Bristol Myers Squibb terminated its manufacturing partnership with automation specialist Cellares after determining its platform couldn't meet requirements for commercial Breyanzi production, triggering layoffs.
Multiple green T cells surrounded by tan-colored cells, depicting immune cell activity. | Image Credit: © k_e_n - stock.adobe.com
Amgen and AstraZeneca announced that the Phase 3 DeLLphi-305 trial met its primary endpoint, with Imdelltra (tarlatamab) plus Imfinzi (durvalumab) significantly improving overall survival versus durvalumab alone as first-line maintenance therapy for extensive-stage small cell lung cancer — the first phase 3 study of a bispecific T-cell engager to show a survival benefit in this earlier-line setting.